The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase.
Wang HY., Malbon CC.
Narrative Review, published in Int J Obes Relat Metab Disord (1996) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Obes Relat Metab Disord (1996)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 8680473
Abstract (original English)
Adipogenesis is the commitment of embryonic stem cells to the highly -differentiated phenotype of the adipocyte, a cell specialized to regulate, in a dynamic fashion, lipid storage. The mouse embryonic 3T3-L1 fibroblasts provide a useful model in which to probe the control differentiation in general and adipogenesis in particular. The G-proteins Gs alpha and Gi alpha 2 have been shown to modulate commitment of fibroblasts to adipocytes in response to inducers such as dexamethasone and meythylisobutylxanthine. Cellular levels of Gs alpha decline sharply in response to inducers as cells commit to the adipogenic phenotype. The molecular strategies of antisense DNA technology and expression of constitutively-activated mutants of Gi alpha 2 reveal that either suppression of Gs alpha or expression of constitutively-active Gi alpha 2 dramatically accelerate the ability of inducers to stimulate adipogenesis or act as inducers themselves. These roles of Gs alpha and Gi alpha 2 are expressed in ambient or elevated intracellular cyclic AMP, demonstrating a critical role of G-proteins in cellular differentiation independent of adenylylcyclase.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.